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Abstract 
The HIV-1 Gag polyprotein, recombinantly expressed in mammalian cell platforms, is self-
assembled, generating HIV-1 Gag virus like particles (VLPs). The expression of HIV-1 Gag 
polyprotein is achieved by DNA/PEI-based transient transfection of HEK 293 cells in 
suspension. Several strategies to improve the VLP production titers have been already described 
such as the so-called extended gene expression methodology (EGE) that extends the production 
phase of the process by the performance of two additional re-transfection rounds to cell culture 
and medium exchanges, providing a 12-fold improvement of Gag VLP production compared to 
batch production. The EGE in combination to the addition of chemical production enhancers 
such as lithium acetate (LiAc), valproic acid (VPA) and caffeine has been reported to increase 
15.6 times the Gag VLP production. However it has been demonstrated that these chemical 
enhancers have a detrimental effect on cell growth and viability. In this study, the use of small 
interfering RNA (siRNA) has been investigated as an alternative to the use of VPA and caffeine. 
Two shRNA sequences against HDAC5 and PDE8A genes, cloned in the expression vector 
containing Gag-GFP gene, were tested. From all tested strategies, only the shRNA substitution 
of VPA was successfully achieved, nevertheless, by the use of this strategy, the toxic effects on 
cell growth and viability provided mainly by VPA addition are avoided. Therefore, the optimum 
strategy is to transfect the cells using the expression vector containing the shRNA sequence 
against the HDAC5 gene, in combination to the addition of caffeine. This novel strategy has 
improved 6.65-fold the Gag VLP production without any negative effect over cell growth or 
viability compared to the standard transient transfection in batch (TGE) mode. Its combination 
with the EGE methodology showed a 40-fold improvement of Gag VLP production compared 
to the TGE mode. Therefore, the developed methodology avoids the toxic effects of VPA 
addition and enables the production of high amount of HIV-1 Gag VLPs. Finally, the impact of 
this improvement on the corresponding bioprocess development is analysed using several 
criteria, demonstrating the elevated potentialities of the developed method.  
Keywords: Transient transfection · Virus-like particles · Extended gene expression · Gene 
silencing · Production optimization 
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1. Nomenclature 
  
VLP Virus like particles 
HIV-1 Human Imunodeficiency Virus -1 
HEK 293 cells Human embryonic kidney 293 cells 
Gag Gag polyprotein 
GFP Green fluorescence protein 
PEI Polyethylenimine 
PTM Post-translational modifications 
siRNA Small interference RNA 
shRNA Short hairpint RNA 
PDE Phosphodiesterasse 
HDAC Histone deacetylase 
TGE Transient gene expression 
EGE Extended gene expression 
LiAc Lithium acetate 
VPA Valproic acid 
VCD Viable cell density 
Hpt Hours post transfection 
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2. Introduction 
Over the last years, mammalian expression systems have become the preferred platform for 
manufacturing biopharmaceuticals, since these cells are able to produce large and complex 
proteins with post-translational modifications (PTM) (Dumont, et al. 2016) and human protein-
like molecular structure assembly (Zhu, et al. 2012). Even so, the use of mammalian cell lines 
as expression system for recombinant protein production has the principal disadvantage that 
lower production titers are obtained in comparison to other expression systems (Brown, et al. 
2017).  Therefore, further optimisation of recombinant protein production is needed. Virus-like 
particles (VLPs) are nanostructures which mimic the native structure of viruses, making them 
recognizable by the immune system. VLPs are composed by the proteins or part of the proteins 
that are forming the virus capsid in actual viruses, but lacking the genomic material. These type 
of new generation vaccines are safer than most conventional viral vaccines (like attenuated or 
inactivated viruses), since the lack of genomic material in VLP particles makes them non-
infective (Fuenmayor, et al. 2017a). In this study the protein of interest is the Gag polyprotein 
from HIV-1, known as the core protein of HIV-1 virus capsid and also one of the three gene 
products which are encoded by all retroviruses (Göttlinger, et al. 2001). After reaching the cell 
nucleus and being expressed, Gag polyprotein accumulates at the vicinity of the cell membrane 
and is self-assembled into VLPs which are released to the media by a budding process. At this 
point, the virus like particles acquire the lipid envelope from the host cell (Cervera, et al. 
2017a). The use of Gag polyprotein as a particle formation machine, combined with the 
expression of different antigens of interest exposed on the host cell membrane, is a commonly 
used platform to produce immunogenic VLPs (Göttlinger, et al. 2001).  
Transfection is the term given to the process of nucleic acid delivery into host cells, and it is 
used to facilitate the expression of exogenous products or the regulation of endogenous cellular 
processes (Brown, et al. 2017). In this work, the production of HIV-1 Gag VLPs is performed 
by transient transfection of HEK 293 cells in culture. Transient gene expression (TGE) 
methodology consists of the transfection of cell culture in batch and the transient expression of 
the protein of interest. Although stable gene expression (SGE) is the most conventional 
methodology to produce recombinant biopharmaceuticals in mammalian production platforms 
industrially, TGE is a suitable procedure to produce the protein of interest in sufficient 
quantities to evaluate recombinant protein candidates in the early stages of its development, in 
pre-clinical batch productions and early phase clinical trials, or other scenarios that demand 
rapid production timelines (Baldi, et al. 2007; Stuible, et al. 2018). Furthermore, in the case of 
genic therapies or personalized treatments, the TGE methodology satisfies the production needs 
without requiring the generation of stable producing clones (Kim, et al. 2010). Even so, the 
obtained product titers in TGE are usually low due to dilution effect associate to cell division. 
The transgene is lost since does not integrate into the cell genome, reducing the production time 
of TGE and limiting the overall production capacity (Cervera, et al. 2015). To avoid this 
limitation of TGE procedure, a methodology called extended gene expression (EGE) was 
developed (Cervera, et al. 2015). In extended gene expression two re-transfections of cell 
culture were carried out 48 and 96 hours after the first transfection, as well as, a medium 
exchange every 48 hours. By this approach, the production phase is extended since the cells that 
were not transfected in the first transfection round, are able to introduce the DNA in second or 
third transfections. In addition, complete medium exchanges allow the maintenance of culture 
viability during longer times (10 days). Additionally, in order to enhance the productivity in 
TGE, some media additives have been used to increase transfection efficiencies (lithium acetate, 
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DMSO, Nocodazole) (Ye, et al. 2009; Tait et al. 2004) or protein production (butyric acid, 
valproic acid, caffeine) (Tait et al. 2004; Backliwal, et al. 2008; Ellis, et al. 2011). In previous 
work, an optimal combination of production enhancers was found for the cell line and VLPs of 
interest here. This combination, which enabled an improvement of 4 fold of Gag VLPs 
production, consists of the addition of lithium acetate, valproic acid and caffeine to the cell 
culture (Cervera, et al. 2015b).  
Lithium acetate (LiAc), increases the transportation of DNA/PEI complexes into the cells by 
changing cell membrane permeability (Ye, et al. 2009). Caffeine has an inhibitory effect over 
phospodiesterases (PDE) and several kinases including ATM (ataxia telangiectasia mutated), 
ATR (ataxia telangiectasia and Rad3-related protein) and DNA-Pks (DNA-dependent protein 
kinase catalytic subunit) (Ellis, et al. 2011). PDE are enzymes that inactivate the intracellular 
cAMP and cGMP (Choi, et al. 1988). The mentioned kinases are important signalling proteins 
involved in the repair of DNA double stranded breaks, and their inactivation has shown a 
positive effect on recombinant production (Ellis, et al. 2011). Valproic acid (VPA) is shown to 
have histone deacetylase (HDAC) inhibitory effect (Backliwal, et al. 2008). HDAC enzymes are 
known to reduce the interaction between histones and DNA by histones deacetylation. Because 
of that, chromatin remains open and transcription is enhanced. Another observed effect of 
HDAC inhibitors over cell culture is that cell cycle is arrested in the phase (G1) preventing cell 
division (Fuenmayor, et al. 2018a; Kaiser et al. 2006). Despite the use of media additives have 
shown clear enhancement of VLP production in previous work, it has also been observed to 
have detrimental effect over cell culture growth and viability when performing EGE 
(Fuenmayor, et al. 2018a). In addition, it is important to realise that its use increases the process 
production and purification costs. Small interfering RNA (siRNA) could be a feasible 
alternative to the use of media additives. When a siRNA sequence is encoded in a DNA plasmid 
is called short hairpin RNA (shRNA), it can be introduced into cultured cells by transfection 
and suppress specific endogenous gene expression (Fuenmayor, et al. 2018a).  Although the 
shRNA effects over the culture, can last for days, they are transient and limited to cells available 
for transfection (Lai, et al. 2008). Inside cells, shRNAs are transcribed and then processed by 
the enzyme DICER resulting in ssRNAs which are complementary to the gene to interfere. 
These ssRNAs bind the mRNAs of this gene and the RNA-induced silencing complex (RISC) 
cuts them preventing their translation. Finally, a knock-down for the specific protein is achieved 
(Lowe, et al. 2011).  
Taking into consideration the described background, this work has two main objectives. First, 
finding an alternative to the use of additives, by using small interfering RNA (siRNA) to 
improve Gag VLP production while maintaining high cell viabilities when performing TGE. 
Second, combining the EGE methodology with the novel alternative to the use of additives, and 
comparing the VLP production obtained in the different systems. In this study, two specific 
shRNA sequences against HDAC5 and PDE8A genes were tested as candidates to be an 
alternative to media additives.  
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3. Materials and methods 
3.1. Cell line, media and culture conditions 
The cell line used in this work is HEK293SF-3F6. It is a serum-free medium suspension-
adapted HEK293 cell line (kindly provided by Dr.Amine Kamen from the BRI of National 
Research Council of Canada and McGill University (Montreal, Canada)), derived from a cGMP 
master cell bank, available for manufacturing of clinical material. The culture medium is 
Freestyle 293 (Invitrogen, Carlsbad, CA, USA) supplemented with 0,1% Pluronic (Invitrogen, 
Carlsbad, CA, USA), 1,6 mg/L of r-transferrin ( Merck Millipore, Kankakee, IL, USA), 19,8 
mg/L of r-insulin (Novo Nordisk Pharmatek , Køge, Denmark.), 0,25 g/L of D-glucose (Merck 
KGaA, Darmstadt, Germany) and 0.9x of an in-house lipid mixture to maximize cell growth and 
productivity (Cervera et al.2013). Cells were cultured in 125-mL disposable polycarbonate 
Erlenmeyer flasks (Corning, Steuben, NY, USA) in 20 mL of culture medium. Flasks were 
shaken at 130 rpm using an orbital shaker (Adolf Kühner AG, Switzerland) mantained at 37º in 
a humidified atmosphere of 5% CO2 in air, inside an incubator (Adolf Kühner AG, 
Switzerland). Cell count and viability were determined by Nucleocounter NC-3000 
(Chemometec, Allerod, Denmark). 
 
3.2. Plasmids and shRNAs 
The plasmid pGag-GFP (named pControl in this work) encodes for a Rev-independent HIV-1 
Gag protein which was previously fused to the enhanced GFP protein (Hermida-Matsumoto and 
Resh 2000) to enable an easy quantification of the produced VLPs. The cloning strategy, 
preparation and purification of Gag-GFP plasmid was previously described (Cervera et al. 
2015b). In order to obtain the different pshRNAs, used in this work, the pGag-GFP plasmid was 
modified. Two specific shRNA sequences against HDAC5 gene (5′CCGGGCCGGGTTTGATGCT 
GTTGAACTCGAGT TCAACAGCATCAAACCCGGCTTTTT 3′) and PDE8A gene (5′ TGCTGTTG 
ACAGTGAGCGAGCTAAGATCATGGTTACAAATTAGTGAAGCCACAGATGTAATTTGTAACC
ATGATCTTAGCGTGCCTACTGCC TCGGATTTTT 3′) were used (Fuenmayor, et al. 2018a). The 
sequence of U6 promoter plus each of the shRNAs were obtained from Gen Script (Nanjing, 
China) and cloned into the pGagGFP in front CMV promoter (Fuenmayor et al. 2018a). The 
developed expression vectors are represented in Fig 1.  The integrity of developed plasmids was 
confirmed running a 1% agarose gel electrophoresis using SYBR safe DNA gel stain 
(Invitrogen). 
3.3. Transient transfection 
Transient transfection was carried out using a 25-kDa linear polyethyleneimine (PEI) 
(PolySciences, Warrington, PA, USA). Before transient transfection, HEK 293 cells were 
grown until reaching a cell concentration of 2x106 cells/ mL. A complete medium exchange was 
performed by centrifuging the cell culture at 300xg for 5 min, prior to transfection. 
Transfections were performed using 1ug/mL of plasmid DNA and 2ug/mL of PEI (1:2 relation) 
(Cervera et al. 2013). The PEI/DNA complexes were formed by adding PEI to plasmid DNA 
previously diluted in fresh culture media without supplementation (10% of the total volume of 
the culture to be transfected). The mixture was incubated for 15 min at room temperature to 
allow complex formation before its addition to the cell culture. The addition of production 
enhancers has been previously described (Cervera et al. 2015b). It was carried out 3 h prior 
transfection for lithium acetate (20 mM) and 4 hours post transfection for valproic acid (3.36 
mM) and caffeine (5.04mM). 
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3.4. Analysis of the percentage of GFP-positive cells 
The percentage of GFP-positive cells was determined in freshly harvested cells every 24 hours 
for TGE protocols and every 48 hours for EGE protocols. The analysis was assessed using a BD 
FACS Canto flow cytometer (BD Biosciences, San Jose, CA, USA). 
3.5. VLP quantitation 
The concentration of Gag-GFP VLPs was assessed by fluorimetry using an in-house developed 
and qualified quantification assay (Gutiérrez-Granados et al. 2013). VLP-containing 
supernatants were recovered by cell culture centrifugation at 1000 xg for 5 min. Green 
fluorescence was measured at room temperature using a Cary Eclipse Fluorescence 
Spectrophotomer (Agilent Technologies, Santa Clara, CA, USA) set as follows: 𝜆ex =488 nm 
(slit 5 nm),  𝜆em= 510 nm (slit 10 nm). Relative fluorescence unit values (RFU) were calculated 
by subtracting fluorescence units (FU) values of untransfected negative control samples. There 
is a linear correlation between fluorescence intensity and p24 values determined using the 
INNOTEST ELISA HIV antigen mAb (Innogenetics NV, Gent, Belgium). RFU values can be 
converted to Gag-GFP concentration values using the following equation:  
 
𝐺𝑎𝑔 − 𝐺𝐹𝑃 (
𝑛𝑔
𝑚𝐿
) = (3.245 × 𝑅𝐹𝑈 − 1.6833 ) × 36     (1) 
 
where Gag-GFP is the estimated concentration of polyprotein and RFU is the measured 
GFP fluorescence intensity in the samples. The first term is the correlation equation 
between fluorescence values and p24 concentrations determined by ELISA and 36 is a 
correction factor that takes into account the difference in molecular weight between p24 
and Gag-GFP and an underestimation arising from using the p24 ELISA to estimate p55 
Gag concentrations. In order to calculate the amount of VLPs per mL, the Gag-GFP 
concentration is divided by the molecular weight of a Gag-GFP monomer (84 kDa) and 
then divided by the number of monomers that a VLP contains (2500 monomers/VLP) 
(Gutiérrez-Granados et al. 2013). 
 
3.6. Cell sorting, total RNA extraction and qPCR analysis  
Freshly harvested cells at 48 hpt were sorted into GFP and non-GFP positive cells using a 
FACSJazz sorter (BD,4480 Biosciences, San Jose, CA, USA). Seventy-five thousand cells were 
sorted for each population and subsequently centrifuged at 300g for 5 min, re-suspended in 
PBS, and stored at − 20 °C. RNA extraction from the samples was carried out using the 
Maxwell® 16 Total RNA Purification Kit (Promega Corporation, Fitchburg, WI). The 
RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA) was 
used to obtain cDNA using 100 ng of total RNA. Relative expression was determined by real-
time polymerase chain reaction (PCR) using the CFX96 Touch™ Real-Time PCR Detection 
System (Bio-Rad Laboratories, Hercules, CA, USA). The mRNA levels were quantified with 
commercial qPCR primers and probes for each studied gene. Single Taqman expression assays 
(Thermo Fisher Scientific, Waltham, MA) were used to quantify HDAC5 (Hs00608351_m1) 
and PDE8A (Hs01079617_m1) mRNA levels. β-Actin (Hs01060665_g1) was used as an 
endogenous control. 
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3.7. Analysis of VLPs by nanoparticle tracking analysis  
Nanoparticle tracking analysis (NTA) was used to determine the amount of correctly assembled 
VLPs of harvest samples using a NanoSight® LM20 device (NanoSight Ltd., Amesbury, UK) at 
the Service of Preparation and Characterization of Soft Materials located at Institut de Ciència 
de Materials de Barcelona (ICMAB, CSIC, Campus UAB). The obtained data was analysed 
with the NanoSight® NTA 2.2 software. Samples were collected and diluted in 0.22 µm-filtered 
PBS prior to the analysis, in order to obtain a sample with a concentration of 108 -109 particles/ 
mL.  
3.8. Calculation of transfection protocols performances 
- VLPs in total harvest (VLPs): 
 
𝑉𝐿𝑃𝑠 =  ∑( [𝑉𝐿𝑃]𝑖 × 𝑉𝑖)    (2) 
where [VLP]i is the VLP concentration (VLPs/mL) of harvest round (i) and Vi is the 
volume (mL) in harvest round (i). 
 
- VLP concentration in total harvest (VLPs/mL): 
 
𝑉𝐿𝑃 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =  
∑( [𝑉𝐿𝑃]𝑖×𝑉𝑖)
∑ 𝑉𝑖
   (3) 
 
- VLP production (VLPs/ hour): 
 
𝑉𝐿𝑃 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 =
 𝑉𝐿𝑃𝑠
𝑡
    (4) 
where t is the production phase of the protocol duration in hours.  
 
- VLP volumetric productivity (VLPs/ hour · mL): 
 
𝑉𝐿𝑃 𝑣𝑜𝑙𝑢𝑚𝑒𝑡𝑟𝑖𝑐 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝑉𝐿𝑃 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛
𝑉𝑇
 (5) 
where VT  is the total harvest volume (mL). 
 
- Specific productivity (VLPs/ cell): 
 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑉𝐿𝑃 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑉𝐶𝐷×𝑓𝑇
  (6) 
where VCD is the concentration of viable cells, expressed in millions of cells/mL, and 
fT is the transfection factor which corresponds to the percentage (between 0 and 1) of 
cells which are transfected, knowing that only transfected cells are able to produce 
VLPs. 
 
3.9. Statistical analyses 
 
All the protocols developed were compared by a t test in order to establish if the improvement 
achieved was statistically significant or not. Microsoft Excel (2010) t test function was used to 
carry out the statistical analyses. 
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4. Results and discussion 
4.1. Comparison of different shRNAs to replace chemical additives in batch 
culture 
The use of shRNA for silencing the genes which are inhibited by the chemical additives, has 
been proposed as an interesting alternative to avoid the observed detrimental effect of 
production enhancers on cell growth and viability (Fuenmayor et al. 2018a). In this study 
specific shRNA sequences against HDAC5 and PDE8A genes have been cloned in the plasmid 
containing the gene of interest (Gag polyprotein from HIV-1) to evaluate their effect on Gag 
VLP production. Three different expression vectors were developed as shown in Fig 1, with 
HDAC5 and PDE8A shRNA sequences cloned either together or alone, in the Gag-GFP 
containing plasmid.  
 
 
 
 
A standard transient transfection protocol in a 72 hours batch (TGE) (Cervera et al. 2013) was 
performed to test the three GagGFP plasmids containing the shRNA sequences (shown in Fig 
1). Transfections were carried out using: pGagGFP with shRNA against HDAC5 gene cloned in 
it (pHDAC), pGagGFP with shRNA against PDE8A gene cloned in it (pPDE), pGagGFP with 
both shRNAs against HDAC5 and PDE8A, cloned together in it (pDouble), pHDAC and pPDE 
transfected together (pHDAC + pPDE) and pGagGFP (pControl). 
The tested pshRNAs had no negative effects on viable cell density and viability of the culture, 
without significant differences between the different conditions tested. As shown in Fig 2A, the 
viable cell density reached after 72 hpt, remains between 5x106 cells/ mL and 6x106 cells /mL in 
all conditions, and the viability was over 90%. For all conditions tested, the percentage of 
transfected cells increased until 48 hpt, reaching, at the end of the batch, a percentage between 
50 and 60% of transfected cells (Fig 2B). As it can be observed in Fig 2C, higher Gag VLP 
production is obtained when transfecting the cells with pHDAC, in comparison to the other 
pshRNA combinations tested. As seen in Fig 2D, the enhancement effect over VLP production 
pControl pHDAC pPDE pDouble 
U6 promoter 
HDAC5 shRNA 
PDE8A shRNA 
Figure 1: Expression vectors. The plasmid Control is formed by Gag-GFP gene preceded by CMV 
promoter. All shRNA have been added to pControl, preceded by U6 promoter. In pHDAC the shRNA 
sequence against HDAC5 gene was added. In the plasmid PDE, was added the shRNA against PDE8A. 
Finally in pDouble, both shRNA sequences (against HDAC5 and PDE8A) were cloned in the same plasmid. 
CMV promoter 
GagGFP 
Poly (A) tail 
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of pPDE was nil, in respect to the production observed when transfecting with pControl 
(6.82x109 and 7.55x109 VLPs/mL, respectively). The pDouble and the condition of pHDAC and 
pPDE transfected together, had a similar effect in the improvement of Gag VLP production 
(1.00x1010 and 1.14x1010 VLPs/mL, respectively), but not as high as the obtained when pHDAC 
was transfected alone (2.09x1010 VLPs/mL). One potential explanation of this observation could 
be that the pDouble, which encodes for both shRNA sequences (against HDAC5 and PDE8A) 
in the same plasmid, experiments stearic limitations that prevent the complete transcription of 
HDAC5 shRNA sequence, therefore, the pDouble design could need to be optimized. In respect 
to the condition of cell transfection with both plasmids at the same time (pHDAC + pPDE 
condition), the need to maintain the optimal ratio 1:2 (w:w) between DNA and PEI to prepare 
the complexes before transfection (Cervera et al. 2013), make not possible to use the same 
amount of pHDAC DNA as in the condition where pHDAC was transfected alone. Because PEI 
has showed to have toxic effect in cells (Cervera et al. 2013; Fliedl, et al. 2011), the pHDAC 
used to transfect the cells was half of the total quantity used for transfect the culture in the 
pHDAC condition. So, one hypothesis could be that the quantity of pHDAC, used for 
transfection, is a determinant factor in the finally obtained Gag VLP production titer. 
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To prove this hypothesis, another standard transient transfection in batch was carried out. Four 
conditions were tested in this experiment: using the standardized quantity of 20 µg of pHDAC 
in complex preparation with PEI (pHDAC), using 10 µg of pHDAC and 10 µg of pControl 
(0.5pHDAC), using 10 µg of pHDAC and 10 µg of pPDE (pHDAC + pPDE) and using 20 µg of 
pGagGFP (pControl), all of them using a DNA/PEI ratio of 1:2. Results are shown in Fig 3. 
The viable cell density reached in all tested conditions was practically the same, achieving after 
72 hpt, a concentration of approximately 5x106 cells / mL. In addition, culture viabilities 
remained high during the whole production process (over 90% of viability) (Fig 3A). As 
observed in the previous experiment, the percentage of transfected cells increased until it 
reached a plateau at 48 hpt. The final percentage of transfected cells was around 60% in all 
conditions (Fig 3B). 
As it can be observed in Fig 3C, the enhancement effect in VLP production of the pHDAC 
condition is considerably higher than the effect observed in 0.5pHDAC condition, evidencing 
that the amount of pHDAC, used in transfection, has a big impact. Furthermore, to support this 
fact, the enhancement effect observed when transfecting with pHDAC and pPDE together, is the 
same as when half of the quantity of pHDAC is used (in 0.5pHDAC condition). As already 
observed in the previous transient transfection experiment carried out, the transfection with 
pPDE did not increase the Gag VLP production. To endorse the obtained results, the effect of 
the shRNA sequences over gene expression was analysed by qPCR of GFP positive cells in 
comparison to the GFP negative population (data not shown). In the GFP positive population 
the shRNA against HDAC5 gene showed to block a 67% of HDAC5 gene expression, but, in 
case of the shRNA against PDE8A gene, no significant inhibition effect of PDE8A expression, 
was observed. As mentioned before, besides the PDE inhibitory effect, it is known that caffeine 
also inhibits several kinases, including ATM601, ATR and DNA-Pks. In previous work (Ellis, 
B. L., et al. 2011), inhibition of this mentioned kinases resulted in increased lentiviral titers in 
HEK 293FT culture. Considering that, in future work it would be interesting to test shRNA 
sequences against ATM601, ATR and DNA-Pks genes as alternatives to caffeine addition. 
After this two TGE series of experiments, it can be concluded that the best pshRNA, is the 
pHDAC (using 20 µg of DNA for complex preparation), since it is the plasmid that showed the 
bigger impact in Gag VLP production in transfected HEK 293 culture, providing a 3-fold 
improvement over the standard TGE (Fig 2D).  
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Figure 3: TGE conditions pHDAC, 0.5pHDAC, pHDAC + pPDE and pControl. A) Viable Cell density 
(solid line) and viability (dotted line). B) Percentage of positive GFP cells. C) Obtained Gag VLP 
production titers. 
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4.2. Evaluation of caffeine addition combined with the transfection with the 
pHDAC plasmid 
As previously discussed, pPDE has not any silencing effect over the PDE8A gene, the addition 
of caffeine (which is reported to inhibit PDE), combined with the transfection with pHDAC, is 
considered to improve the obtained Gag VLP production titers. In this novel protocol, cells were 
transfected with pHDAC and caffeine was added 4 hpt. From now on, for simplicity, this novel 
approach will be referred as (pHDAC + caffeine). This condition was compared with the 
standard protocol using all additives (Cervera et al. 2015b) (Additives), with pGagGFP with 
caffeine addition 4 hpt (pControl + caffeine), pHDAC transfected alone (pHDAC) and 
pGagGFP also transfected alone (pControl).  
 
The obtained results are shown in Figure 4. Similar viable cell densities and viabilities were 
observed in all conditions except for Additives condition, were VCD did not increase after 24 
hpt (Fig 4A). It has been previously described that the addition of VPA to the cell culture, 
arrests cells in the phase (G1), avoiding its division (Fuenmayor et al. 2018a; Wu, et al. 2008; 
Kaiser, et al. 2006). After 24 hpt, viability started to decrease in Additives’ condition, due to the 
toxicity of media additives on cells (Fig 4A). The percentage of transfected cells has no 
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significant variations between all conditions tested, reaching the maximum number of 
transfected cells 48 hours post transfection (with 40 to 50 % of transfected cells) (Fig 4B).  
In Fig 4C it can be observed that the condition pHDAC + caffeine had the highest VLP 
production compared to the other tested conditions. Higher VLP production titers were obtained 
when comparing with the culture transfected with pGagGFP (pControl), (5,02x1010 VLPs/ mL 
for pHDAC + caffeine condition and 7,55x109 VLPs/mL for pControl condition). The pControl 
+ Caffeine condition showed minor enhancement over VLP production than the ones observed 
in  pHDAC+ Caffeine and Additives conditions, indicating that pHDAC has a positive effect on 
VLP production enhancement, independently of the addition of caffeine. In the Additives 
condition, where LiAc, VPA and caffeine were added, it can be seen that, until 48 hpt, similar 
VLP production to pHDAC + caffeine is obtained. Even so, at 72 hpt, VLP production in 
Additives condition decreases, compared to the obtained when transfecting the cell culture with 
pHDAC + caffeine. This may be due to the observed decrease in viability after 24 hpt in 
Additives condition (Fig 4B).  
Table 2: Amount of obtained Gag VLPs and specific productivity of the performed TGE protocols. The 
fold improvement given by the developed protocols is statistically significant (p value < 0.5). 
 
VLPs/ cell*   VLPs 
Improvement 
(VLPs) 
Standard 3090 1,51E+11 1 
Additives 23800 6,82E+11     (p value < 0,0002) 4,52 
pHDAC 9980 4,50E+11     (p value < 0,002) 3 
pHDAC + Caff 26600 1,00E+12    (p value < 0,00003) 6,65 
* Transfected cells 
Table 2 summarizes the amount of obtained Gag VLPs and specific productivities of the 
performed TGE protocols. The use of pHDAC + caffeine is the best option as it provides a 6.65-
fold improvement of Gag VLP production in comparison to the standard protocol (where cells 
were transfected with pControl). When performing the Additives condition, an improvement in 
VLP production of 4.52-fold was obtained, confirming results from previous work (Cervera, et 
al. 2015b). The pHDAC + caffeine and Additives protocols showed similar specific 
productivities, both higher than the specific productivity given by the standard TGE. So, in both 
conditions, the production capacity of transfected cells was increased by the inhibition of 
HDAC and PDE expression. Therefore, the VPA’s enhancement effect in Gag VLP production, 
observed in Additives condition, is achieved in this novel condition by the use of shRNA 
against HDAC5 gene. Moreover, the addition of caffeine in this condition, supplies the lack of 
an efficient shRNA against PDE8A, increasing the impact over Gag VLP production of the 
condition of transfection with pHDAC. 
Taking into account all the obtained results, the best pshRNA combination to carry out the 
transient gene expression protocol (TGE) with an enhanced Gag VLP production, is the 
protocol where the cells are transfected with pHDAC with the addition of caffeine 4 hpt.  
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4.3. Combination of extended gene expression with pHDAC + caffeine strategy 
As previously discussed, extended gene expression protocol (EGE) enables that cells that have 
not been transfected in first transfection, are able of being transfected in the subsequent 
transfection rounds. In previous studies, a 12-fold increase in the Gag VLP production in EGE 
in relation to the production in TGE has been reported (Cervera, et al. 2015a). Even more, it has 
been previously described a 1.4-fold improvement of Gag VLP production titer when carrying 
out the EGE protocol with the addition of production enhancers (VPA, lithium acetate and 
caffeine) (Fuenmayor et al. 2018a). Even so, the use of these media additives made the non-
transfected cells not able to incorporate the DNA in second and third transfections, reducing 
EGE + additives protocol Gag VLP production potential (Fuenmayor et al. 2018a). Since 
shRNA only cause a gene silencing effect over transfected cells of the culture, the non-
transfected cells population is susceptible of being transfected in subsequent transfection 
rounds, making the use of shRNA a good alternative to the addition of production enhancers. 
For this reason, the selected pshRNA configuration after the performed TGEs, pHDAC + 
caffeine strategy, was tested in combination with EGE protocol.  
A standard EGE and EGE pHDAC + Caffeine were carried out. As shown in Fig 5, two rounds 
of re-transfection were performed at 48 and 96 hours post first transfection in both conditions 
tested, as well as, a medium exchange of the culture every 48 hours. In re-transfection rounds, 
cells were re-transfected with only 0.5 µg of plasmid DNA/mL instead of the 1 µg of plasmid 
DNA/mL, used in the first transfection (Cervera, et al. 2015a).   
Figure 5: Diagram of performed standard EGE and EGE pHDAC + caffeine protocols, respectively. 
Where ME means complete medium exchange. For both protocols three transfection rounds are 
performed at 0, 48 and 96 hpt. In EGE pHDAC + caffeine protocol caffeine is added 4 hpt in every 
transfection round. Five harvest rounds (with a complete media replacement) are carried out every 48 
hours.  
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Similar percentages of transfected cells were observed in the two conditions tested, achieving 
the maximum values (between 45 and 55 %) after 48 hours post first transfection (as shown in 
Fig 6A). The achieved VCD when EGE pHDAC + Caffeine protocol was performed was lower 
than the one reached performing the EGE protocol. As well, culture viability, after 144 hours 
post transfection, decreases in major extend in EGE pHDAC + Caffeine condition than in EGE 
condition, dropping under 50% after 240 hpt (Fig 6B). Therefore, the addition of caffeine to the 
culture has a slightly detrimental effect over cells in comparison to when no additives are added. 
This observed negative effect was not as significant as the previously observed over cell culture 
growth and viability when EGE protocol combined with VPA and caffeine addition was carried 
out (Fuenmayor et al. 2018a).  
 
Fig 6C shows the Gag VLP production titers for EGE and EGE pHDAC + Caffeine. As it can 
be seen, the use of pHDAC for transfecting the cells, with the addition of caffeine 4 hours post 
transfection (EGE pHDAC + Caffeine) had a great impact over Gag VLP production in 
comparison to production obtained transfecting with pControl (standard EGE). In Fig 6C it can 
be observed that, until 48 hours after the last re-transfection round (144 hours post first 
transfection), the VLP production in the condition EGE pHDAC+ caffeine was much higher 
than the one in EGE condition. After that, a decrease in VLP production titer obtained in EGE 
Figure 6: EGE pHDAC + caffeine and standard EGE protocols. A) Viable Cell density (solid line) and 
viability (dotted line). B) Percentage of positive GFP cells. C) Obtained Gag VLP production titers in 
every harvest round (performed every 48 hours). D) Accumulated VLPs and fold improvement (of 
obtained  VLPs) of EGE pHDAC + caffeine protocol over standard EGE protocol. 
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pHDAC + caffeine condition was observed, achieving similar values than in the EGE protocol. 
Nevertheless, the concentration of VLPs obtained during all the experiment when transfecting 
with pHDAC and adding caffeine, is higher than the obtained in EGE condition. In Fig 6D it 
can be observed the total Gag VLPs obtained in the two protocols tested, as well as the fold 
improvement provided by EGE pHDAC+ caffeine protocol over EGE protocol. At the end of 
the experiment carried out, a total amount of 2.07x1012 VLPs was achieved in EGE pHDAC + 
caffeine condition, in contrast to the 6.20x1011 VLPs obtained in EGE. In fact, the performed 
EGE pHDAC + caffeine protocol provided a 3.34-fold improvement compared with the 
standard EGE protocol. As it can be observed in Fig 6D, the improvement provided by pHDAC 
+ caffeine protocol is higher at the beginning of the experiment and decreases over the time. 
This observed decrease in VLP production improvement and the decrease in VLP production 
titer obtained in EGE pHDAC + caffeine (shown in Fig 6C) may be due to two phenomena: In 
first place, the transfected episomal DNA, which does not integrate into cell genome, is lost 
over time as a consequence of cell division, when no more re-transfection rounds are performed 
(Cervera, et al. 2015a); in second place, the adaptation of the transfected cells that, after several 
days of cultivation, are able to find alternative pathways to bypass the interfered route (silenced 
HDAC5 gene). 
The performance of transfection process carrying out standard EGE and EGE pHDAC + 
caffeine protocols is summarized in Table 3. The novel EGE pHDAC + caffeine protocol offers 
clear advantages over the used standard EGE protocol in terms of total VLP concentration 
(VLPs/ mL), VLPs in total harvest (VLPs), VLP production (VLPs/hour), volumetric 
productivity (VLPs/h · mL) and specific productivity (VLPs/ cell). 
Table 3: Comparison of standard EGE and EGE pHDAC + caffeine protocols transfection performances. 
The fold improvement given by EGE pHDAC + caffeine protocol is statistically significant (p value < 
0.5). 
 
EGE 
pGag-GFP 
EGE 
pHDAC + caffeine 
Improvement 
Total VLP concentration (VLPs/mL) 
(in total harvest) 
6,20E+09 
2,07E+10   
(p value < 0,00002) 
3,34 
VLPs in total harvest (VLPs) 6,20E+11 2,07E+12 
VLP production (VLPs/hour) 2,58E+09 8,63E+09 
Volumetric productivity (VLPs/h · mL) 2,58E+07 8,63E+07 
Specific productivity (VLPs/ cell*) 827 5450 6,59 
* Transfected cells 
The EGE optimized protocol (EGE pHDAC + caffeine), after a production phase that lasted 240 
hours, provided an amount of  VLPs 3.34 times higher as the one obtained performing standard 
EGE protocol, during the same production time. In the same way, the observed improvement in 
total VLP concentration, production and volumetric productivity is also 3.34 since in both 
performed EGE protocols the used reactor volume (100 mL) and production time (240 hours) 
are the same. As seen before, when carrying out a TGE protocol in batch, the specific 
productivity of cells which were transfected with pHDAC + caffeine is higher than in cells 
transfected with pGagGFP (6.59-folds) (Table 2), proving that the inhibition effect over HDAC 
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and PDE genes, provided by this optimized protocol, enhances the VLP production potential of 
each transfected cell. Nevertheless, the specific productivities obtained for EGE protocols are 
lower than the obtained for TGE protocols. A potential explanation of this fact could be that the 
cell cultures in EGE protocols are able to achieve higher VCD than in TGE protocols and the 
used shake flasks system is not able to satisfy the nutritional demands of the culture. As a 
consequence of that the VLP production potential of transfected cells is being reduced. 
4.4. Evolution of produced VLP quality 
In previous work, when performing transient gene expression, it has been described an increase 
of free Gag-GFP monomers in supernatant over time (Gutiérrez-Granados, et al. 2013). As 
culture viability decreases, the disrupted cells release to the media free Gag-GFP monomers and 
proteases, which are able to degrade assembled VLPs, and therefore, compromise the quality of 
the product. Because of that, it becomes an important point to stop the production process when 
the culture viability remains high (Cervera, et al. 2017). So, the determination of optimum 
extended gene expression (EGE) duration is an agreement between high VLP production titers 
and quality of produced VLPs. 
VLP quality throughout the performed EGE and EGE pHDAC + caffeine, was analysed to 
determine the best duration time of the novel developed EGE protocol. Released Gag-GFP 
monomers, as a consequence of cellular lysis, increase the detected fluorescence in supernatant 
(Gutiérrez-Granados, et al. 2013).  For this reason, a nanoparticle tracking analysis (NTA), 
which can detect nanoparticles according to their size and fluorescence, was carried out and 
compared to the results obtained from the fluorimetry quantitation assay (shown in Fig 6C) to 
determine the variation of the percentage of assembled Gag VLPs in supernatant over time (data 
not shown). Complete Gag VLPs were detected in supernatants of both protocols after NTA 
assay (Fig 7). As seen in fluorimetry quantification assay (Fig 6D), higher accumulated Gag 
VLP are obtained when performing EGE pHDAC + caffeine than in standard EGE protocol. For 
standard EGE, the percentage of Gag VLPs over free Gag-GFP monomers, decreased 
approximately a 20% since the culture viability dropped under 80%, from 96 hpt to the end of 
the production phase (240 hpt). In EGE pHDAC + caffeine condition, the percentage of 
assembled VLPs over free monomers was lower than the one observed in standard EGE 
condition, mainly due to the lower viability observed during all production phase (Fig 6B). 
Nevertheless, in this case, a decrease in the percentage of assembled VLPs was not observed 
until 240 hours post transfection. At this point, the percentage of VLPs decreased roughly a 
28%. Therefore, regarding the obtained results about the product quality, it was decided to 
exclude the fifth harvest round performed at 240 hpt in EGE pHDAC + caffeine protocol, 
afterwards, the quality of produced VLPs started to decrease. 
Figure 7: Complete Gag VLPs detected by NTA assay with a mean particle size between 100 and 250 
nm (marked with white arrows). The images a), b), c), d) and e) correspond to samples of EGE pHDAC + 
caffeine protocol, harvested at 48, 96, 144, 192 and 240 hpt, respectively. The images f), g), h), i) and j) 
correspond to samples of Standard EGE protocol, harvested at 48, 96, 144, 192 and 240 hpt, respectively. 
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4.5. Production process optimization and implementation 
As previously discussed, the determination of the optimum duration of EGE pHDAC + caffeine 
protocol should balance the final amount of produced VLPs and their quality. Based on the 
observed results of the evolution of the VLPs’ quality over the production phase, it is proposed 
as design criteria to exclude the fifth harvest round (240 hpt) of the EGE pHDAC + caffeine 
production protocol, stopping the process at 192 hpt. Nevertheless, as shown in Fig 5A, the 
obtained VLP production titer in the fourth harvest round (192 hpt) of  EGE pHDAC + caffeine  
protocol was considerably lower than the obtained in the previous harvest rounds (48 hpt, 96 hpt 
and 144 hpt). Therefore, to optimize the production process it is important to analyse the 
possibility of eliminating the fourth harvest round, stopping the process at 144 hpt. For this 
reason, the obtained VLP productivity during one year (VLPs/ mL· year) has been calculated 
while performing the EGE pHDAC + caffeine  protocol carrying out 3 harvest rounds (stopping 
the process at 144 hpt) or 4 harvest rounds (stopping the process at 192 hpt) (Table 4).  
Table 4: Comparison of the performances of EGE pHDAC + caffeine protocol considerin the 
performance of  3 or 4 harvest rounds. In the calculations it is considered a gap of two days between two 
consecutive production phases. 
 3 harvest rounds 4 harvest rounds 
Process duration (days) 6  8  
VLP concentration/ process (VLPs/ mL) 
(in total harvest) 
2,80E+10 2,41E+10 
Required volume/ process (mL) 60 80 
Obtained VLPs/ process 1,68E+12 1,93E+12 
Number of processes/ year 45 36 
VLP productivity (VLPs/ mL · year ) 1,26E+12 8,68E+11 
 
As shown in Table 4, by carrying out 3 harvest rounds in EGE pHDAC + caffeine protocol, 
higher number of processes can be performed per year, compared to the case of performing 4 
harvest rounds (45 processes/ year instead of the 36 processes/ year). Despite more VLPs per 
process are obtained by the performance of 4 harvest rounds, the VLP concentration is higher 
when carrying out only 3 harvest rounds (2.80x1010 VLPs/mL instead of 2.41x1010 VLPs/mL). 
As a result, the amount of VLPs produced in one year, carrying out only 3 harvest rounds, is 
higher than the obtained by performing 4 harvest rounds (1.26x1012 and 8.69x1011 VLPs/ mL· 
year, respectively). As the fourth harvest round did not had a big impact on the final amount of 
VLPs, it has been decided to also exclude this harvest round of EGE pHDAC + caffeine 
protocol, performing only 3 harvest rounds and stopping the process at 144 hpt.  
The use of the optimized EGE pHDAC + caffeine protocol, could improve the production 
process, considerably reducing its costs. Fig 8A shows a Gantt diagram of the VLP production 
process performing EGE pHDAC + caffeine, standard EGE and standard TGE protocols. To 
produce the same amount of Gag VLPs achieved in EGE pHDAC + caffeine protocol, 
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performing the standard EGE protocol and considering two days gap between processes for 
cleaning, sterilization and cell amplification, it would require 4.5-fold the time needed for the 
EGE pHDAC + caffeine strategy (34 days instead of 6 days). Furthermore, the time required to 
produce this quantity of VLPs by performing a standard TGE protocol would be 5.6-fold the 
required in EGE pHDAC + caffeine protocol (54 days instead of 6 days). In addition, the 
volume of medium needed for this optimized protocol would be more than 6 times lower than 
the required to carry out standard EGE protocol and  4.3-fold lower than the needed for TGE 
protocol. Additionally, the plasmid amount to perform all the transfection rounds would be also 
3 times lower than in standard EGE protocol (40 ug of plasmid DNA instead of 120 ug) and 6.5 
times lower compared to the used in standard TGE protocol ( 260 ug of plasmid DNA). When it 
comes to the downstream process, as the product obtained in EGE pHDAC + caffeine protocol 
is more concentrated than in standard EGE and TGE protocols, it would need less effort to 
separate it. In addition, the use of a shRNA strategy that avoids VPA addition could further ease 
downstream process, reducing the number of purification steps.  
The development and optimization of transfection methodologies, regarding the large number of 
variables that affect transfection processes, are commonly carried out at small scale using non-
instrumented shake flasks. Once the optimum conditions to perform the transfection protocol 
are fixed, the next step is the scale-up of the process to obtain the desired production (Gutiérrez-
Granados, et al. 2018). Therefore, the implementation of the HIV-1 Gag VLP production by the 
optimized extended gene expression protocol (pHDAC + caffeine) at bioreactor will be 
performed in future work. In previous work, EGE to produce HIV-1 Gag VLPs has been 
successfully performed in a 1.35 L perfusion operated bioreactor (Fuenmayor, et al. 2018b), 
achieving similar transfection efficiency and VLP production titer, as well as higher specific 
productivity when comparing to the production in shake flasks. As mentioned before, the used 
EGE methodology in shake flasks consists in complete media exchange every 48 hours, when 
cells are centrifuged and separated from the supernatant and fresh medium is fed. Therefore, 
cells are provided by new nutrients, cell metabolites are removed from the culture media and 
VLPs are harvested. Nevertheless, centrifugation operation becomes more cumbersome at larger 
production scales and the risk of contamination of the cell culture increases. Perfusion is the 
proposed mode of operation for the implementation of this methodology at bioreactor scale, 
enabling a continuous removal of waste products, feeding of nutrients and VLPs harvest, and as 
a consequence, prolonging the production phase (Fuenmayor, et al. 2018b). Fig 8B shows a 
scheme of the optimized HIV-1 Gag VLPs production process run for a perfusion operated 
bioreactor. In the proposed process the cell culture is previously amplified and seeded into the 
bioreactor. Then the culture is grown in the bioreactor until reaching the desired VCD (2x106 
cells/ mL), required for optimal cell transfection. The complex formation between pHDAC and 
PEI is carried out in a separated tank prior to transfection. The DNA/PEI complexes are fed into 
the bioreactor to transfect the cells in every transfection round. The perfusion is performed at a 
flow rate of 0.5 vvd (volume of harvest per working volume per day) (considering that in the 
EGE protocol performed in shake flasks, complete media exchanges were carried out every 48 
hours). By this way, the bioreactor is continuously fed by fresh medium and the produced VLPs 
are harvested in the outlet current and collected in an independent tank. By operating in 
perfusion mode, the harvest and recovery of produced VLPs is performed at the same time, 
while the cells are retained inside the bioreactor. Perfusion can be carried out by several devices 
such as sedimentation (i.e. acoustic settle), filtration (tangential flow filtration (TFF) or 
alternating tangential flow (ATF) using i.e. Hollow fibre filter [HF]), spin-filter and crossflow 
microfiltration (Fuenmayor, et al. 2018b; Warkiani, et al. 2014; Clincke, et al. 2013).  
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Figure 8: A) Gantt diagram of Gag VLP production process performing EGE pHDAC + caffeine, 
standard EGE and standard TGE protocols to produce 1.68x1012 VLPs (the VLP quantity achieved after 
144hpt in EGE pHDAC + caffeine protocol). The considered duration of production processes is 144 
hours for the EGE pHDAC + caffeine protocol, 240 hours for EGE protocol and 72 hours for TGE 
protocol. Two days for cleaning sterilization and cell amplification between productions have been 
considered. B) Scheme of the production of HIV-1 Gag VLPs in a perfusion operated reactor. 1- 
DNA/PEI complex formation tank. 2- Fresh medium continuously fed to the bioreactor at a flow rate of 
0.5 vvd. 3- Bioreactor. 4- Perfusion device to retain the cells from the supernatant containing the product. 
5- Thank of VLPs harvest in the supernatant at a constant flow rate of 0.5 vvd. C) Diagram of the 
operation mode of the proposed HIV-1 Gag VLP production in a perfusion operated bioreactor. 
  
Fig 8C shows a diagram of the proposed mode of operation of the perfusion reactor. In every 
transfection round the perfusion would be stopped and would be resumed 2 hours after caffeine 
addition (which is added 4 hpt), giving time to the DNA/PEI complexes and caffeine to enter 
5 
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into the cells. In perfusion configuration cells are constantly fed, allowing to maintain higher 
viability during longer time. In addition, the product is also constantly harvested, reducing its 
residence time inside the bioreactor. Therefore, the product quality may not be as compromised 
as in the processes carried out in batch mode (Gutiérrez-Granados, et al. 2018), so, further 
analysis of produced VLPs quality at bioreactor scale would be needed to determine the 
optimum process duration. In addition, in previous work (Fuenmayor, et al. 2018b), due to high 
cell growth, large amount of non-transfected cells were observed while performing EGE in 
bioreactor, suggesting that more re-transfection rounds could be carried out, increasing the VLP 
production titers.  
 
5. Conclusion 
The use of a shRNA against the HDAC5 gene cloned in pGag-GFP has shown to have a great 
impact in Gag VLP production while performing TGE methodology. As discussed before, the 
shRNA against the PDE8A gene did not enhance the VLP production when transfected into cell 
culture cloned in Gag-GFP plasmid (pPDE). Considering that, it would be interesting to test 
shRNA sequences against ATM601, ATR and DNA-Pks genes cloned into pGag-GFP as 
potential candidates to substitute the caffeine addition. Another possibility to study is to clone 
both shRNA sequences (against the HDAC5 and against one of the mentioned kinases) together 
in pGag-GFP. So, more work towards this direction is needed to obtain a completely optimized 
protocol to produce HIV-1 Gag VLP which supplies all of the used production enhancers. 
The addition of caffeine when carrying out TGE pHDAC protocol has shown to increase the 
obtained VLP production titer without any detrimental effect on culture viability or cell growth. 
Moreover, while performing the EGE pHDAC protocol, the addition of caffeine provided the 
biggest improvement in produced VLPs in comparison to the produced in standard EGE 
protocol. Nevertheless, a slight diminution of cell growth and viability, comparing with the 
standard EGE, was observed due to caffeine addition.  
The utilization of gene silencing strategies (shRNA against the HDAC5 gene) combined with 
caffeine addition in EGE protocol (EGE pHDAC + caffeine) enabled to develop an efficient 
methodology which is more than four times faster than the formerly used one (standard EGE) 
and also less intensive in medium and DNA requirements. The proposed strategy provides 
higher improvement of produced HIV-1 Gag VLPs compared to the improvement achieved 
when using the EGE protocol combined with the VPA an caffeine addition (3.34-fold and 1.4-
fold improvement over standard EGE protocol, respectively) (Fuenmayor, et al. 2018a).  In 
addition, the developed strategy provides a 40-fold improvement of produced VLPs compared 
to the standard TGE, avoiding the previously mentioned limitations of the addition of 
production enhancers to the media (Fuenmayor, et al. 2018a).   
An optimum time duration of 144 hours has been determined to implement this novel strategy 
for the production process, with three re-transfections and harvest rounds, according to the 
observed evolution of product quality over time and the VLP production titer obtained in each 
harvest round. 
Based on the obtained results, the potential of a production process based on the developed 
methodology has been considered. In a bioreactor of 2 L, a yearly production of 5.6x1013 VLPs 
could be attained, with a production phase of 6 days and consuming a total volume of medium 
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of 8 L (considering that the perfusion is operated at a flow rate of 0.5 vvd). Nevertheless, due to 
the previously commented benefits of operating in perfusion mode, more re-transfection rounds 
could be performed and also the production phase could be prolonged, increasing the VLP 
production potential of the process.  
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